Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561232 | 0.86 | MEN1 (0.42) | IDO1HTTSLC6A4HTR2AMEN1 | |
| SCHEMBL13756279 | 0.85 | HTR2C (0.41) | IDO1AGXT | |
| SCHEMBL22519887 | 0.84 | HTT (0.43) | IDO1AGXTHTTCYP1A2CYP2C9 | |
| SCHEMBL29018344 | 0.81 | IDO1 (0.45) | IDO1HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30517263 | 0.81 | IDO1 (0.45) | IDO1HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13318415 | 0.80 | MAPT (0.46) | IDO1HTTCYP2C9TBXA2RCYP2C19 | |
| SCHEMBL6505160 | 0.80 | IDO1 (0.41) | IDO1AGXTCYP1A2CYP2C9TBXA2R | |
| SCHEMBL12936616 | 0.79 | IDO1 (0.38) | IDO1AGXTCYP1A2CYP2C9TBXA2R | |
| SCHEMBL27112677 | 0.79 | IDO1 (0.42) | IDO1AGXTCYP1A2CYP2C9TBXA2R | |
| SCHEMBL706473 | 0.79 | IDO1 (0.64) | IDO1AGXTHTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078352-A1 | CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021013800-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | IDO1 1285/4885AGXT 3690/4885HTT 1571/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | IDO1 1285/4885AGXT 3690/4885HTT 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.